Note 2 - Basis of Presentation

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Business Description and Basis of Presentation [Text Block]

2. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in accordance with accounting principles generally accepted in the United States (“US GAAP”). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. The

December 

31,

2016

balances reported herein are derived from the audited consolidated financial statements. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed consolidated financial position of the Company as of

September 30, 2017,

the results of its operations for the

three

- and

nine

-month periods ended

September 30, 2017

and

2016,

and cash flows for the

nine

-month periods ended

September 30, 2017

and

2016.

The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s annual financial statements filed with its Annual Report on Form 

10

-K for the year ended

December 31, 2016.

The results of operations for the

nine

-month period ended

September 30, 2017

are

not

necessarily indicative of the results to be expected for the year ending

December 

31,

2017.

Certain prior period amounts have been reclassified to conform to the current period presentation. This change in classification does

not

materially affect previously reported cash flows from operations or from financing activities in the Condensed Consolidated Statement of Cash Flows, and had

no

effect on the previously reported Condensed Consolidated Statement of Operations and Comprehensive Income.